Pharsight

Ovide generic

Ovide is an anti-lice drug owned by Taro Pharm Inds Ltd. The active ingredient is malathion. Ovide was first authorized for market use on August 2, 1982.

When will Ovide generic be available?

The generics of Ovide are likely to be released after February 1, 2027. This is following the expiration of the last patent (US7560445), titled 'Process for preparing malathion for pharmaceutical use.'

Ovide uses

Ovide, containing malathion, is used for the treatment of patients infected with pediculus humanus capitis, commonly known as head lice and their eggs, on the scalp hair. It is available in the form of a topical lotion.

Ovide patent expiration

Ovide has a total of 2 drug patents. The last patent (US7560445) titled 'Process for preparing malathion for pharmaceutical use' is due to expire on February 1, 2027, paving the way for the release of the Ovide generic. Below are the details of the patent:

Ovide dosage

Want to ask something?